Takaki Maeda MD, Presenter: Nothing to Disclose

Hajimu Goto MD, PhD, Abstract Co-Author: Nothing to Disclose

Hitomi Hara MD, PhD, Abstract Co-Author: Nothing to Disclose

Toshihiro Akisue MD, PhD, Abstract Co-Author: Nothing to Disclose

Teruya Kawamoto MD, PhD, Abstract Co-Author: Nothing to Disclose

Yasuo Oh-nishi MD, PhD, Abstract Co-Author: Nothing to Disclose

Yuki Iwama MD, Abstract Co-Author: Nothing to Disclose

Masahiro Kurosaka, Abstract Co-Author: Nothing to Disclose

Kazuro Sugimura MD, PhD, Abstract Co-Author: Research Grant, Toshiba Corporation Research Grant, Koninklijke Philips NV Research Grant, Bayer AG Research Grant, Eisai Co, Ltd Research Grant, DAIICHI SANKYO Group

The purpose of this study was to determine the Gadlinium concentration remaining in human bone tissue after administration of typical Gadolinium contrast agent such as macrocyclic (Gd-DOTA) or linear (Gd-DTPA-BMA) chelate at a standard clinical dose and to evaluate the relationships with renal function.

Eleven patients underwent contrast-enhanced MRI before surgical resection of bone tumor. Nine male patients and two female patients aged between 13 to 43 years old. Patients divided into two groups (Gd-DTPA-BMA-group and Gd-DOTA-group). After administration of 0.1mmol Gd/kg of Gd-DTPA-BMA (n=5) or Gd-DOTA (n=6) to patients with bone tumor undergoing surgical resection, bone specimens (normal tissues in the resection margin of tumor) were collected and analyzed Gd concentration by Inductively Coupled Plasma Mass Spectrometry (ICP-MS). Surgical resection of bone tumor was performed within 8 to 14days after MRI. Renal function (eGFR) in each patients was evaluated before MRI examination. Gd concentration in bone tissue and eGFR were compared Gd-DTPA-BMA group with Gd-DOTA group. The differences between the Gd-DTPA-BMA group and Gd-DOTA group were determined using a non-paired t-test. Statistical significance was difined as p < 0.05.

Bone tissue retention of Gd was 625.2±374.5ng Gd/g for Gd-DTPA-BMA group versus 141.7±91.5 ng Gd/g for Gd-DOTA group, and statistically significant difference of Gd concentration in bone was observed (*p <0.05). However, there was no stasistically significant difference in eGFR(83.2±5.6 versus 86.2±12.5 ml/min/1.73m2) and the number of days before surgery (11.9±0.9 versus 11.2±2.5 days).

Typical linear Gd chelate, Gd-DTPA-BMA left approximately 4.4 times more Gd behind in bone than did macrocyclic Gd chelate, Gd-DOTA.

In patients within normal range of eGFR, Gd retention in bone tissue is significantly different between linear chelate and macrocyclic chelate Gd based contrast agent.

Maeda, T, Goto, H, Hara, H, Akisue, T, Kawamoto, T, Oh-nishi, Y, Iwama, Y, Kurosaka, M, Sugimura, K, Comparison of Gd-DTPA-BMA versus Gd-DOTA of Gadolinium Retention in Human Bone Tissue with Normal Renal Function.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14010816.html